Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
Interferon a (human leukocyte protein moiety reduced). A type I interferon consisting of 165 amino acid residues with lysine in position 23. This protein is produced by recombinant DNA technology and resembles interferon secreted by leukocytes. It is used extensively as an antiviral or antineoplastic agent. An oral form is being developed by Amarillo Biosciences.
The global average price of Interferon Alpha-2a Biosimilar is in the decreasing trend, from 186.78 USD/Unit in 2013 to 64.67 USD/Unit in 2017. With the situation of global economy, prices will be in decreasing trend in the following five years.The classification of Interferon Alpha-2a Biosimilar includes ordinary type and long-lasting type, and the proportion of ordinary type in 2017 is about 64%, and the proportion is in increasing trend from 2013 to 2017.Interferon Alpha-2a Biosimilar is widely used for hepatitis C, hepatitis B and other diseases. The most proportion of Interferon Alpha-2a Biosimilar is used for hepatitis C, and the proportion in 2017 is 46%. Europe is the largest supplier of Interferon Alpha-2a Biosimilar, with a production market share nearly 70% in 2017. South America is the largest consumption place, with a consumption market share nearly 26% in 2017. Following South America, Europe is the second largest consumption place with the consumption market share of 22%. Market competition is not intense. 3sbio, Zydus Cadila, PROBIOMED, Rhein Minapharm Biogenetics, Biosidus, Amega Biotech, Nanogen, Roche, etc. are the leaders of the industry, and they hold key technologies and patents, with high-end customers; have been formed in the monopoly position in the industry.
This report offers an overview of the market trends, drivers, and barriers with respect to the China Interferon Alpha-2a Biosimilar market. It also provides a detailed overview of the market of different regions across North China, Central China, South China, East China, Northeast China, Southwest China, Northwest China. The report deep analyzes type and application in China Interferon Alpha-2a Biosimilar market. Detailed analysis of key players, along with key growth strategies adopted by Interferon Alpha-2a Biosimilar industry, the PEST and SWOT analysis are also included. In short, the report will provide a comprehensive view of the industry's development and features.
By Player:
3sbio
Zydus Cadila
PROBIOMED
Rhein Minapharm Biogenetics
Biosidus
Amega Biotech
Nanogen
Roche
By Type:
Long-lasting Type
Ordinary Type
By End-User:
Hepatitis C
Hepatitis B
Other
By Region:
-
North China
-
Central China
-
South China
-
East China
-
Northeast China
-
Southwest China
-
Northwest China
TABLE OF CONTENT
1 Report Overview
-
1.1 Product Definition and Scope
-
1.2 PEST (Political, Economic, Social and Technological) Analysis of Interferon Alpha-2a Biosimilar Market
-
1.3 Market Segment by Type
-
1.3.1 China Interferon Alpha-2a Biosimilar Market Size and Growth Rate of Long-lasting Type from 2016 to 2027
-
1.3.2 China Interferon Alpha-2a Biosimilar Market Size and Growth Rate of Ordinary Type from 2016 to 2027
-
1.4 Market Segment by Application
-
1.4.1 China Interferon Alpha-2a Biosimilar Market Size and Growth Rate of Hepatitis C from 2016 to 2027
-
1.4.2 China Interferon Alpha-2a Biosimilar Market Size and Growth Rate of Hepatitis B from 2016 to 2027
-
1.4.3 China Interferon Alpha-2a Biosimilar Market Size and Growth Rate of Other from 2016 to 2027
-
1.5 Market Segment by Regions
-
1.5.1 North China Interferon Alpha-2a Biosimilar Consumption Market Size and Growth Rate from 2016 to 2027
-
1.5.2 Central China Interferon Alpha-2a Biosimilar Consumption Market Size and Growth Rate from 2016 to 2027
-
1.5.3 South China Interferon Alpha-2a Biosimilar Consumption Market Size and Growth Rate from 2016 to 2027
-
1.5.4 East China Interferon Alpha-2a Biosimilar Consumption Market Size and Growth Rate from 2016 to 2027
-
1.5.5 Northeast China Interferon Alpha-2a Biosimilar Consumption Market Size and Growth Rate from 2016 to 2027
-
1.5.6 Southwest China Interferon Alpha-2a Biosimilar Consumption Market Size and Growth Rate from 2016 to 2027
-
1.5.7 Northwest China Interferon Alpha-2a Biosimilar Consumption Market Size and Growth Rate from 2016 to 2027
2 Market Trends and Competitive Landscape
-
2.1 Market Trends and Dynamics
-
2.1.1 Market Challenges and Restraints
-
2.1.2 Market Opportunities and Potentials
-
2.1.3 Mergers and Acquisitions
-
2.2 Competitive Landscape Analysis
-
2.2.1 Industrial Concentration Analysis
-
2.2.2 Porter's Five Forces Analysis of the Industry
-
2.2.3 SWOT Analysis for New Entrants
-
2.3 Coronavirus (COVID-19) Distribution and its Impact on the Industry
3 Segmentation of Interferon Alpha-2a Biosimilar Market by Types
-
3.1 Products Development Trends of Different Types
-
3.2 Commercial Products Types of Major Vendors
-
3.3 Competitive Landscape Analysis of Different Types
-
3.4 Market Size of Interferon Alpha-2a Biosimilar by Major Types
-
3.4.1 Market Size and Growth Rate of Long-lasting Type
-
3.4.2 Market Size and Growth Rate of Ordinary Type
4 Segmentation of Interferon Alpha-2a Biosimilar Market by End-Users
-
4.1 Downstream Client Analysis by End-Users
-
4.2 Competitive Landscape Analysis of Different End-Users
-
4.3 Market Potential Analysis of Different End-Users
-
4.4 Market Size of Interferon Alpha-2a Biosimilar by Major End-Users
-
4.4.1 Market Size and Growth Rate of Interferon Alpha-2a Biosimilar in Hepatitis C
-
4.4.2 Market Size and Growth Rate of Interferon Alpha-2a Biosimilar in Hepatitis B
-
4.4.3 Market Size and Growth Rate of Interferon Alpha-2a Biosimilar in Other
5 Market Analysis by Regions
-
5.1 China Interferon Alpha-2a Biosimilar Production Analysis by Regions
-
5.2 China Interferon Alpha-2a Biosimilar Consumption Analysis by Regions
-
5.3 Coronavirus (COVID-19) Impact on China Economy
6 North China Interferon Alpha-2a Biosimilar Landscape Analysis
-
6.1 North China Interferon Alpha-2a Biosimilar Landscape Analysis by Major Types
-
6.2 North China Interferon Alpha-2a Biosimilar Landscape Analysis by Major End-Users
7 Central China Interferon Alpha-2a Biosimilar Landscape Analysis
-
7.1 Central China Interferon Alpha-2a Biosimilar Landscape Analysis by Major Types
-
7.2 Central China Interferon Alpha-2a Biosimilar Landscape Analysis by Major End-Users
8 South China Interferon Alpha-2a Biosimilar Landscape Analysis
-
8.1 South China Interferon Alpha-2a Biosimilar Landscape Analysis by Major Types
-
8.2 South China Interferon Alpha-2a Biosimilar Landscape Analysis by Major End-Users
9 East China Interferon Alpha-2a Biosimilar Landscape Analysis
-
9.1 East China Interferon Alpha-2a Biosimilar Landscape Analysis by Major Types
-
9.2 East China Interferon Alpha-2a Biosimilar Landscape Analysis by Major End-Users
10 Northeast China Interferon Alpha-2a Biosimilar Landscape Analysis
-
10.1 Northeast China Interferon Alpha-2a Biosimilar Landscape Analysis by Major Types
-
10.2 Northeast China Interferon Alpha-2a Biosimilar Landscape Analysis by Major End-Users
11 Southwest China Interferon Alpha-2a Biosimilar Landscape Analysis
-
11.1 Southwest China Interferon Alpha-2a Biosimilar Landscape Analysis by Major Types
-
11.2 Southwest China Interferon Alpha-2a Biosimilar Landscape Analysis by Major End-Users
12 Northwest China Interferon Alpha-2a Biosimilar Landscape Analysis
-
12.1 Northwest China Interferon Alpha-2a Biosimilar Landscape Analysis by Major Types
-
12.2 Northwest China Interferon Alpha-2a Biosimilar Landscape Analysis by Major End-Users
13 Major Players Profiles
-
13.1 3sbio
-
13.1.1 3sbio Company Profile and Recent Development
-
13.1.2 Market Performance
-
13.1.3 Product and Service Introduction
-
13.2 Zydus Cadila
-
13.2.1 Zydus Cadila Company Profile and Recent Development
-
13.2.2 Market Performance
-
13.2.3 Product and Service Introduction
-
13.3 PROBIOMED
-
13.3.1 PROBIOMED Company Profile and Recent Development
-
13.3.2 Market Performance
-
13.3.3 Product and Service Introduction
-
13.4 Rhein Minapharm Biogenetics
-
13.4.1 Rhein Minapharm Biogenetics Company Profile and Recent Development
-
13.4.2 Market Performance
-
13.4.3 Product and Service Introduction
-
13.5 Biosidus
-
13.5.1 Biosidus Company Profile and Recent Development
-
13.5.2 Market Performance
-
13.5.3 Product and Service Introduction
-
13.6 Amega Biotech
-
13.6.1 Amega Biotech Company Profile and Recent Development
-
13.6.2 Market Performance
-
13.6.3 Product and Service Introduction
-
13.7 Nanogen
-
13.7.1 Nanogen Company Profile and Recent Development
-
13.7.2 Market Performance
-
13.7.3 Product and Service Introduction
-
13.8 Roche
-
13.8.1 Roche Company Profile and Recent Development
-
13.8.2 Market Performance
-
13.8.3 Product and Service Introduction
The List of Tables and Figures
-
Figure Product Picture
-
Figure China Interferon Alpha-2a Biosimilar Market Size and Growth Rate of Long-lasting Type from 2016 to 2027
-
Figure China Interferon Alpha-2a Biosimilar Market Size and Growth Rate of Ordinary Type from 2016 to 2027
-
Figure Market Share by Type in 2016
-
Figure Market Share by Type in 2021
-
Figure Market Share by Type in 2027
-
Figure China Interferon Alpha-2a Biosimilar Market Size and Growth Rate of Hepatitis C from 2016 to 2027
-
Figure China Interferon Alpha-2a Biosimilar Market Size and Growth Rate of Hepatitis B from 2016 to 2027
-
Figure China Interferon Alpha-2a Biosimilar Market Size and Growth Rate of Other from 2016 to 2027
-
Figure Market Share by End-User in 2016
-
Figure Market Share by End-User in 2021
-
Figure Market Share by End-User in 2027
-
Figure North China Interferon Alpha-2a Biosimilar Consumption Market Size and Growth Rate from 2016 to 2027
-
Figure Central China Interferon Alpha-2a Biosimilar Consumption Market Size and Growth Rate from 2016 to 2027
-
Figure South China Interferon Alpha-2a Biosimilar Consumption Market Size and Growth Rate from 2016 to 2027
-
Figure East China Interferon Alpha-2a Biosimilar Consumption Market Size and Growth Rate from 2016 to 2027
-
Figure Northeast China Interferon Alpha-2a Biosimilar Consumption Market Size and Growth Rate from 2016 to 2027
-
Figure Southwest China Interferon Alpha-2a Biosimilar Consumption Market Size and Growth Rate from 2016 to 2027
-
Figure Northwest China Interferon Alpha-2a Biosimilar Consumption Market Size and Growth Rate from 2016 to 2027
-
Figure Development Trends and Industry Dynamics of Interferon Alpha-2a Biosimilar Industry
-
Figure Market Challenges and Restraints
-
Figure Market Opportunities and Potentials
-
Table Mergers and Acquisition
-
Figure Market Share of TOP 3 Players in 2020
-
Figure Market Share of TOP 5 Players in 2021
-
Figure Market Share of TOP 6 Players from 2016 to 2021
-
Figure Porter's Five Forces Analysis
-
Figure New Entrant SWOT Analysis
-
Figure Coronavirus (COVID-19) Map of China
-
Table Coronavirus (COVID-19) Impact on the Industry
-
Figure Specifications of Different Types of Interferon Alpha-2a Biosimilar
-
Figure Development Trends of Different Types
-
Table Commercial Products Types of Major Vendors
-
Figure Competitive Landscape Analysis of Different Types
-
Table Consumption of Interferon Alpha-2a Biosimilar by Different Types from 2016 to 2027
-
Table Consumption Share of Interferon Alpha-2a Biosimilar by Different Types from 2016 to 2027
-
Figure Market Size and Growth Rate of Long-lasting Type
-
Figure Market Size and Growth Rate of Ordinary Type
-
Table Downstream Client Analysis by End-Users
-
Figure Competitive Landscape Analysis of Different End-Users
-
Table Market Potential Analysis of Different End-Users
-
Figure Consumption of Interferon Alpha-2a Biosimilar by Different End-Users from 2016 to 2027
-
Table Consumption Share of Interferon Alpha-2a Biosimilar by Different End-Users from 2016 to 2027
-
Figure Market Size and Growth Rate of Hepatitis C
-
Figure Market Size and Growth Rate of Hepatitis B
-
Figure Market Size and Growth Rate of Other
-
Table China Interferon Alpha-2a Biosimilar Production by Regions
-
Table China Interferon Alpha-2a Biosimilar Production Share by Regions
-
Figure China Interferon Alpha-2a Biosimilar Production Share by Regions in 2016
-
Figure China Interferon Alpha-2a Biosimilar Production Share by Regions in 2021
-
Figure China Interferon Alpha-2a Biosimilar Production Share by Regions in 2027
-
Table China Interferon Alpha-2a Biosimilar Consumption by Regions
-
Table China Interferon Alpha-2a Biosimilar Consumption Share by Regions
-
Figure China Interferon Alpha-2a Biosimilar Consumption Share by Regions in 2016
-
Figure China Interferon Alpha-2a Biosimilar Consumption Share by Regions in 2021
-
Figure China Interferon Alpha-2a Biosimilar Consumption Share by Regions in 2027
-
Table North China Interferon Alpha-2a Biosimilar Consumption by Types from 2016 to 2027
-
Table North China Interferon Alpha-2a Biosimilar Consumption Share by Types from 2016 to 2027
-
Figure North China Interferon Alpha-2a Biosimilar Consumption Share by Types in 2016
-
Figure North China Interferon Alpha-2a Biosimilar Consumption Share by Types in 2021
-
Figure North China Interferon Alpha-2a Biosimilar Consumption Share by Types in 2027
-
Table North China Interferon Alpha-2a Biosimilar Consumption by End-Users from 2016 to 2027
-
Table North China Interferon Alpha-2a Biosimilar Consumption Share by End-Users from 2016 to 2027
-
Figure North China Interferon Alpha-2a Biosimilar Consumption Share by End-Users in 2016
-
Figure North China Interferon Alpha-2a Biosimilar Consumption Share by End-Users in 2021
-
Figure North China Interferon Alpha-2a Biosimilar Consumption Share by End-Users in 2027
-
Table Central China Interferon Alpha-2a Biosimilar Consumption by Types from 2016 to 2027
-
Table Central China Interferon Alpha-2a Biosimilar Consumption Share by Types from 2016 to 2027
-
Figure Central China Interferon Alpha-2a Biosimilar Consumption Share by Types in 2016
-
Figure Central China Interferon Alpha-2a Biosimilar Consumption Share by Types in 2021
-
Figure Central China Interferon Alpha-2a Biosimilar Consumption Share by Types in 2027
-
Table Central China Interferon Alpha-2a Biosimilar Consumption by End-Users from 2016 to 2027
-
Table Central China Interferon Alpha-2a Biosimilar Consumption Share by End-Users from 2016 to 2027
-
Figure Central China Interferon Alpha-2a Biosimilar Consumption Share by End-Users in 2016
-
Figure Central China Interferon Alpha-2a Biosimilar Consumption Share by End-Users in 2021
-
Figure Central China Interferon Alpha-2a Biosimilar Consumption Share by End-Users in 2027
-
Table South China Interferon Alpha-2a Biosimilar Consumption by Types from 2016 to 2027
-
Table South China Interferon Alpha-2a Biosimilar Consumption Share by Types from 2016 to 2027
-
Figure South China Interferon Alpha-2a Biosimilar Consumption Share by Types in 2016
-
Figure South China Interferon Alpha-2a Biosimilar Consumption Share by Types in 2021
-
Figure South China Interferon Alpha-2a Biosimilar Consumption Share by Types in 2027
-
Table South China Interferon Alpha-2a Biosimilar Consumption by End-Users from 2016 to 2027
-
Table South China Interferon Alpha-2a Biosimilar Consumption Share by End-Users from 2016 to 2027
-
Figure South China Interferon Alpha-2a Biosimilar Consumption Share by End-Users in 2016
-
Figure South China Interferon Alpha-2a Biosimilar Consumption Share by End-Users in 2021
-
Figure South China Interferon Alpha-2a Biosimilar Consumption Share by End-Users in 2027
-
Table East China Interferon Alpha-2a Biosimilar Consumption by Types from 2016 to 2027
-
Table East China Interferon Alpha-2a Biosimilar Consumption Share by Types from 2016 to 2027
-
Figure East China Interferon Alpha-2a Biosimilar Consumption Share by Types in 2016
-
Figure East China Interferon Alpha-2a Biosimilar Consumption Share by Types in 2021
-
Figure East China Interferon Alpha-2a Biosimilar Consumption Share by Types in 2027
-
Table East China Interferon Alpha-2a Biosimilar Consumption by End-Users from 2016 to 2027
-
Table East China Interferon Alpha-2a Biosimilar Consumption Share by End-Users from 2016 to 2027
-
Figure East China Interferon Alpha-2a Biosimilar Consumption Share by End-Users in 2016
-
Figure East China Interferon Alpha-2a Biosimilar Consumption Share by End-Users in 2021
-
Figure East China Interferon Alpha-2a Biosimilar Consumption Share by End-Users in 2027
-
Table Northeast China Interferon Alpha-2a Biosimilar Consumption by Types from 2016 to 2027
-
Table Northeast China Interferon Alpha-2a Biosimilar Consumption Share by Types from 2016 to 2027
-
Figure Northeast China Interferon Alpha-2a Biosimilar Consumption Share by Types in 2016
-
Figure Northeast China Interferon Alpha-2a Biosimilar Consumption Share by Types in 2021
-
Figure Northeast China Interferon Alpha-2a Biosimilar Consumption Share by Types in 2027
-
Table Northeast China Interferon Alpha-2a Biosimilar Consumption by End-Users from 2016 to 2027
-
Table Northeast China Interferon Alpha-2a Biosimilar Consumption Share by End-Users from 2016 to 2027
-
Figure Northeast China Interferon Alpha-2a Biosimilar Consumption Share by End-Users in 2016
-
Figure Northeast China Interferon Alpha-2a Biosimilar Consumption Share by End-Users in 2021
-
Figure Northeast China Interferon Alpha-2a Biosimilar Consumption Share by End-Users in 2027
-
Table Southwest China Interferon Alpha-2a Biosimilar Consumption by Types from 2016 to 2027
-
Table Southwest China Interferon Alpha-2a Biosimilar Consumption Share by Types from 2016 to 2027
-
Figure Southwest China Interferon Alpha-2a Biosimilar Consumption Share by Types in 2016
-
Figure Southwest China Interferon Alpha-2a Biosimilar Consumption Share by Types in 2021
-
Figure Southwest China Interferon Alpha-2a Biosimilar Consumption Share by Types in 2027
-
Table Southwest China Interferon Alpha-2a Biosimilar Consumption by End-Users from 2016 to 2027
-
Table Southwest China Interferon Alpha-2a Biosimilar Consumption Share by End-Users from 2016 to 2027
-
Figure Southwest China Interferon Alpha-2a Biosimilar Consumption Share by End-Users in 2016
-
Figure Southwest China Interferon Alpha-2a Biosimilar Consumption Share by End-Users in 2021
-
Figure Southwest China Interferon Alpha-2a Biosimilar Consumption Share by End-Users in 2027
-
Table Northwest China Interferon Alpha-2a Biosimilar Consumption by Types from 2016 to 2027
-
Table Northwest China Interferon Alpha-2a Biosimilar Consumption Share by Types from 2016 to 2027
-
Figure Northwest China Interferon Alpha-2a Biosimilar Consumption Share by Types in 2016
-
Figure Northwest China Interferon Alpha-2a Biosimilar Consumption Share by Types in 2021
-
Figure Northwest China Interferon Alpha-2a Biosimilar Consumption Share by Types in 2027
-
Table Northwest China Interferon Alpha-2a Biosimilar Consumption by End-Users from 2016 to 2027
-
Table Northwest China Interferon Alpha-2a Biosimilar Consumption Share by End-Users from 2016 to 2027
-
Figure Northwest China Interferon Alpha-2a Biosimilar Consumption Share by End-Users in 2016
-
Figure Northwest China Interferon Alpha-2a Biosimilar Consumption Share by End-Users in 2021
-
Figure Northwest China Interferon Alpha-2a Biosimilar Consumption Share by End-Users in 2027
-
Table Company Profile and Development Status of 3sbio
-
Table Sales, Revenue, Sales Price and Gross Margin Analysis of 3sbio
-
Figure Sales and Growth Rate Analysis of 3sbio
-
Figure Revenue and Market Share Analysis of 3sbio
-
Table Product and Service Introduction of 3sbio
-
Table Company Profile and Development Status of Zydus Cadila
-
Table Sales, Revenue, Sales Price and Gross Margin Analysis of Zydus Cadila
-
Figure Sales and Growth Rate Analysis of Zydus Cadila
-
Figure Revenue and Market Share Analysis of Zydus Cadila
-
Table Product and Service Introduction of Zydus Cadila
-
Table Company Profile and Development Status of PROBIOMED
-
Table Sales, Revenue, Sales Price and Gross Margin Analysis of PROBIOMED
-
Figure Sales and Growth Rate Analysis of PROBIOMED
-
Figure Revenue and Market Share Analysis of PROBIOMED
-
Table Product and Service Introduction of PROBIOMED
-
Table Company Profile and Development Status of Rhein Minapharm Biogenetics
-
Table Sales, Revenue, Sales Price and Gross Margin Analysis of Rhein Minapharm Biogenetics
-
Figure Sales and Growth Rate Analysis of Rhein Minapharm Biogenetics
-
Figure Revenue and Market Share Analysis of Rhein Minapharm Biogenetics
-
Table Product and Service Introduction of Rhein Minapharm Biogenetics
-
Table Company Profile and Development Status of Biosidus
-
Table Sales, Revenue, Sales Price and Gross Margin Analysis of Biosidus
-
Figure Sales and Growth Rate Analysis of Biosidus
-
Figure Revenue and Market Share Analysis of Biosidus
-
Table Product and Service Introduction of Biosidus
-
Table Company Profile and Development Status of Amega Biotech
-
Table Sales, Revenue, Sales Price and Gross Margin Analysis of Amega Biotech
-
Figure Sales and Growth Rate Analysis of Amega Biotech
-
Figure Revenue and Market Share Analysis of Amega Biotech
-
Table Product and Service Introduction of Amega Biotech
-
Table Company Profile and Development Status of Nanogen
-
Table Sales, Revenue, Sales Price and Gross Margin Analysis of Nanogen
-
Figure Sales and Growth Rate Analysis of Nanogen
-
Figure Revenue and Market Share Analysis of Nanogen
-
Table Product and Service Introduction of Nanogen
-
Table Company Profile and Development Status of Roche
-
Table Sales, Revenue, Sales Price and Gross Margin Analysis of Roche
-
Figure Sales and Growth Rate Analysis of Roche
-
Figure Revenue and Market Share Analysis of Roche
-
Table Product and Service Introduction of Roche
-
